Partnerships can transform the trajectory of a health-tech startup. Johanna Majamaa, CEO of GekkoVet discusses how working with Royal Canin enabled the company to validate its platform across 100 clinics, demonstrate real-world impact, and lay the groundwork for expansion into new markets and universities.
Milestone - Collaboration
Technology
Partnerships
Companion
Veterinary
Johanna Majamaa
Chief Executive Officer
Gekko Vet Oy
Securing the right exit is critical to ensuring innovation achieves full market potential. Louise Grubb, Managing Director of TriviumVet, shares how the company balanced growth milestones, resisted low valuations, and leveraged regulatory success to secure the right partner at the right time to achieve sustainable scale post-acquisition.
Milestone - Acquisition
Companion
Feline
Canine
Cardiovascular
Renal
Pain
Gastro
Acquisition
Exit
Louise Grubb
CEO & Co-Founder
TriviumVet
Nutrition is emerging as a powerful tool for preventing disease and strengthening immunity in livestock. Changemakers leading this shift explore the opportunities and hurdles that will shape evidence generation, farmer adoption, and the scaling of preventative nutrition across global production systems.
- Evidence generation – building the data to prove measurable impact on health and productivity
- Scaling adoption – integrating precision nutrition into commercial production systems
Panellists
Aaron Schacht
CEO
BiomEdit
Philippe Tramoy
Partner
Seventure Partners
Monoclonal antibodies are redefining therapeutic possibilities in animal health, offering precise, targeted alternatives to traditional treatments. With next-generation innovation expanding into new disease areas and species, changemakers at the forefront examine the opportunities and hurdles that will shape development, approval, and adoption.
- Regulatory pathways – navigating approval processes for novel biologics
- Clinical adoption – driving veterinary education and confidence in new therapies
Panellists
Denise Bevers
President & CEO
VETmAb Biosciences, Inc
Steve Nanchen
Senior Director, External Innovation EU & APAC Pacific
Elanco
Antimicrobial resistance is one of the most urgent challenges in animal and human health, demanding new approaches beyond traditional antibiotics. Changemakers developing preventative strategies and non-antibiotic alternatives explore the opportunities and hurdles that will define how these tools expand the veterinary toolkit, reduce dependence, and safeguard vital medicines.
- Market positioning – differentiating alternatives from traditional antibiotics
- Adoption drivers – proving cost-effectiveness and securing veterinary and farmer buy-in
Panellists
Tom Weaver
Co-Founder & Chairman
PetMedix & ArkVax